Breaking Down Yunnan Baiyao Group Co.,Ltd Financial Health: Key Insights for Investors

Yunnan Baiyao Group's mid-2025 results demand attention: first-half operating revenue reached RMB 21.257 billion (up 3.92% YoY) and TTM revenue to Sept 30, 2025 was RMB 40.77 billion (3.65% YoY), while net profit attributable to the parent in H1 2025 rose 13.93% to RMB 3.633 billion giving a net margin of 17.1% and basic EPS of RMB 2.04; balance-sheet strength shows total assets of RMB 54.535 billion with shareholders' net assets of RMB 40.407 billion and a conservative asset-liability ratio of 25.91%, supported by cash and bank balances of RMB 11.294 billion, operating cash flow of RMB 3.961 billion (up 21.45% YoY), a current ratio of 2.5 and quick ratio of 1.8; market metrics include a market cap of RMB 99.44 billion (Dec 10, 2025), P/E of 20.5, P/S of 2.44, EV/EBITDA of 10.2, an estimated intrinsic value per share of RMB 71.8 and a dividend yield of 3.5% with a 2024 payout ratio of 90.09%; investors should weigh these figures alongside risks - regulatory shifts, raw-material price swings, competition and supply-chain vulnerabilities - and growth levers such as a 33% increase in R&D to RMB 2 billion in 2024, a target for overseas sales to reach 15% of revenue by 2025, Smart Factory recognition by the World Economic Forum, and diversification through digital channels and YNBY International Limited to assess the company's investment case

Yunnan Baiyao Group Co.,Ltd (000538.SZ) - Revenue Analysis

• Revenue growth trajectory: H1 2025 +3.92% YoY; TTM Sep 30, 2025 +3.65% YoY; 2024 +2.36% YoY.
• Scale efficiency: ~RMB 4.39M revenue generated per employee, indicating high revenue intensity for the workforce size.
• Valuation context: P/S = 2.44 with market cap ~RMB 99.44B, implying the market prices roughly 2.44x annual sales.

Yunnan Baiyao Group Co.,Ltd (000538.SZ) - Profitability Metrics

• Net profit attributable to the parent company: RMB 3.633 billion (H1 2025), +13.93% YoY.
• Net profit margin: 17.1% (H1 2025) vs 15.8% (H1 2024).
• Gross profit margin: 29.1% (H1 2025) vs 28.3% (H1 2024).
• Operating profit margin: 15.2% (H1 2025) vs 14.5% (H1 2024).
• Basic EPS: RMB 2.04 (H1 2025), +13.97% YoY.
• Weighted average return on net assets (ROE): 9.09% (H1 2025), +1.16 percentage points YoY.

Yunnan Baiyao Group Co.,Ltd (000538.SZ) - Debt vs. Equity Structure

• Total assets: RMB 54.535 billion
• Net assets attributable to shareholders: RMB 40.407 billion
• Asset-liability ratio: 25.91%
• Total share capital (end of Q2 2025): 1,784,262,603 shares
• State-owned Equity Management Company increased holdings (Aug 2024): 17,807,463 shares (~0.998% of total share capital)
• Special dividend (Nov 2024): RMB 12.13 per 10 shares
• Dividend payout ratio (2024): 90.09%

• Capital structure implication: with an asset-liability ratio of 25.91% and net assets of RMB 40.407 billion, equity is the dominant funding source; balance-sheet resilience is high.
• Shareholder returns: a near-100% payout policy in 2024 (90.09% payout ratio plus a substantial special dividend) signals prioritization of cash returns over aggressive reinvestment.
• Strategic ownership moves: the State-owned Equity Management Company's ~0.998% increase in Aug 2024 provides both ownership stability and potential alignment with broader policy interests.

Yunnan Baiyao Group Co.,Ltd (000538.SZ) Liquidity and Solvency

• Operating cash growth: +21.45% YoY to RMB 3.961 billion (H1 2025).
• Cash & bank balance: RMB 11.294 billion at reporting-date.
• Current ratio: 2.5 - indicates ample short-term asset coverage versus current liabilities.
• Quick ratio: 1.8 - confirms liquidity strength without relying on inventory conversion.
• Interest coverage ratio: 12.5 - comfortably covers interest expense, lowering solvency risk.
• Cash conversion cycle: 45 days - reflects efficient working capital management.

• Investor takeaway: high operating cash growth plus RMB 11.294 billion cash position underpin financial flexibility for investment or debt reduction.
• Risk points to monitor: sustained operating cash trends, inventory turns versus quick ratio stability, and any changes to interest-bearing debt that could alter coverage metrics.

Yunnan Baiyao Group Co.,Ltd (000538.SZ) - Valuation Analysis

Core valuation metrics and returns paint a picture of a sizable, profit-generating healthcare conglomerate trading at moderate valuation multiples while offering income to shareholders.

• Trailing twelve months P/E: 20.5 - reflects investor willingness to pay for current earnings.
• EV/EBITDA: 10.2 - indicates reasonable valuation relative to operating cash profits.
• Market capitalization (as of 2025-12-10): RMB 99.44 billion.
• Estimated intrinsic value per share: RMB 71.8 - implies potential undervaluation versus market price if shares trade below this level.
• Dividend yield: 3.5% - provides recurring cash return to equity holders.
• Return on equity (ROE): 15.3% - demonstrates efficient use of shareholder capital.

• Valuation context: a P/E of 20.5 paired with EV/EBITDA of 10.2 typically signals a middle-ground valuation - not cheap relative to growth names, yet not stretched versus stable profit contributors.
• Income and profitability: a 3.5% dividend yield combined with 15.3% ROE supports a case for both income-focused and return-on-equity-focused investors.
• Intrinsic vs. market: the RMB 71.8 intrinsic estimate is the central reference for assessing upside or downside versus the prevailing market price; consider share count and float dynamics when translating intrinsic per-share into aggregate value.

Further company background and operational context can be found here: Yunnan Baiyao Group Co.,Ltd: History, Ownership, Mission, How It Works & Makes Money

Yunnan Baiyao Group Co.,Ltd (000538.SZ) Risk Factors

Investors assessing Yunnan Baiyao Group Co.,Ltd (000538.SZ) should weigh specific operational, market and financial risks that can materially affect future performance. Below are the principal risk areas, supported by recent financial context and sensitivity details.

• Regulatory change risk: pharmaceutical pricing, approval timelines and GMP enforcement can affect product launches and margins.
• Raw material price volatility: key herbal and chemical inputs can drive cost of goods sold fluctuations.
• Competitive pressure: the TCM and OTC markets are crowded with national and regional rivals, pressuring volumes and pricing.
• FX exposure: international sales and imports expose the company to RMB exchange rate moves.
• Supply chain and logistics disruptions: single-source ingredients, manufacturing interruptions or logistics bottlenecks can curtail supply.
• Shifts in consumer preferences: moves toward alternative therapies or different distribution channels (e‑commerce vs. pharmacies) can change product demand.

Key recent financial indicators (illustrative snapshot):

Practical risk scenarios and potential investor impacts:

• Regulatory tightening: a new round of drug re-evaluations or pricing cuts could delay product approvals and reduce near‑term revenue; a 5-10% hit to annual revenue is plausible in an adverse scenario where several SKUs are affected.
• Raw material shock: a 20-30% increase in key herb prices could erode gross margin by several percentage points, cutting net profit proportionally unless offset by price increases.
• Market share erosion: intensified discounting by competitors or entry of national pharma groups into TCM niches could pressure volume growth and force higher marketing spend.
• Currency moves: a sustained RMB appreciation could reduce competitiveness of exports; a 5% FX swing can move reported international revenue by similar magnitude in RMB terms.
• Supply chain interruption: prolonged supplier or logistics failures could reduce sales by mid-single digits in affected quarters and increase emergency procurement costs.
• Consumer preference shifts: accelerated moves to non‑traditional channels or alternative therapies could require reallocation of CAPEX and marketing, impacting short-term margins.

Monitoring checklist for investors (leading indicators):

• Regulatory filings and announcement cadence for product approvals or recalls.
• Management commentary on raw material procurement and hedging strategies.
• Channel mix trends-retail pharmacy vs. e‑commerce sales growth rates.
• Changes in export sales, FX hedging disclosures and trade exposure.
• Supplier concentration disclosures and inventory turnover metrics.
• R&D pipeline updates and new product launch timing.

Contextual reading: Yunnan Baiyao Group Co.,Ltd: History, Ownership, Mission, How It Works & Makes Money

Yunnan Baiyao Group Co.,Ltd (000538.SZ) - Growth Opportunities

• International expansion: target for overseas sales to contribute 15% of total revenue by 2025 via channels including YNBY International Limited.
• R&D ramp-up: 2024 R&D spend rose 33% to RMB 2.0 billion, with a pipeline aimed at delivering ~10 new products annually.
• Digital and omnichannel: pilots of integrated online-offline retail and exploration of digital sales platforms to broaden reach and improve customer acquisition/retention.
• Advanced manufacturing: Smart Factory recognized in the World Economic Forum's Global Lighthouse Network, underscoring scalable, tech-enabled production capability.
• Academic & institutional partnerships: strategic alliances with universities and research institutions to modernize TCM formulations and accelerate clinical/technical validation.
• Diversification: move into e‑commerce and overseas markets through units such as YNBY International Limited to create new revenue streams and reduce domestic concentration risk.